Tardive Dyskinesia News

Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure
SAN DIEGO, May 17, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated ...
New Neupro® Data in Parkinson's Disease and Restless Legs Syndrome to be Presented at the 64th American Academy of ...
ATLANTA, April 20, 2012 /PRNewswire/ -- Data examining the effect of Neupro® (rotigotine transdermal system) in both Parkinson's disease and Restless Legs Syndrome (RLS) will be presented at the 64th American ...
Neurocrine Biosciences Reports First Quarter 2012 Results
SAN DIEGO, May 2, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced its financial results for the quarter ended March 31, 2012.  For the first quarter of 2012, the Company ...
Neurocrine Biosciences To Present At The Deutsche Bank 37th Annual Health Care Conference
SAN DIEGO, May 4, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting ...
Research and Markets: Diabetic Gastroparesis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Research and Markets has announced the addition of GlobalData's new report "Diabetic Gastroparesis Therapeuti
Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
SAN DIEGO, April 25, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the Company will report its first quarter 2012 financial results after the Nasdaq market closes ...
Medicure Reports Third Quarter 2012 Financial Results
Medicure Reports Third Quarter 2012 Financial Results
Mylan Launches Generic Version of Zyprexa® Tablets
PITTSBURGH, April 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL - News) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration ...
Dainippon Sumitomo Pharma Reports that Latuda® (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase ...
Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression .
New Study Shows Patients Can Effectively be Switched to Latuda® (lurasidone HCl) from Other Antipsychotic Agents
Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA .